Not applicableStudy completedNCT05853432
What this trial is testing
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
Who this might be right for
HR+/HER2- Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals 157